Emily Sabath

发表

Mouse model systems of autism spectrum disorder: Replicability and informatics signature

D. Brunner, E. Sabath, K. Cox, 2019, bioRxiv.

Insights into the structural determinants required for high-affinity binding of chiral cyclopropane-containing ligands to α4β2-nicotinic acetylcholine receptors: an integrated approach to behaviorally active nicotinic ligands.

D. Brunner, A. Smit, R. Lukas, 2012, Journal of medicinal chemistry.

In vivo phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents

Liming Shao, Kerry L. Spear, N. Powell, 2016 .

Comprehensive Analysis of the 16p11.2 Deletion and Null Cntnap2 Mouse Models of Autism Spectrum Disorder

Wim E Crusio, Anirvan Ghosh, D. Brunner, 2015, PloS one.

Characterization of maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitors as stimulators of steroidogenesis.

Dani Brunner, D. Brunner, V. Papadopoulos, 2013, Journal of medicinal chemistry.

SAHA Enhances Synaptic Function and Plasticity In Vitro but Has Limited Brain Availability In Vivo and Does Not Impact Cognition

Kimberly Scearce-Levie, Dani Brunner, Qiang Zhou, 2013, PloS one.

Large-scale phenome analysis defines a behavioral signature for Huntington's disease genotype in mice

M. MacDonald, D. Brunner, J. Gusella, 2016, Nature Biotechnology.

Comprehensive Analysis of Two Shank3 and the Cacna1c Mouse Models of Autism Spectrum Disorder

D. Brunner, W. Spooren, V. Alexandrov, 2016, bioRxiv.

The potent and selective α4β2*/α6*-nicotinic acetylcholine receptor partial agonist 2-[5-[5-((S)Azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol demonstrates antidepressive-like behavior in animal models and a favorable ADME-tox profile

D. Brunner, R. Lukas, A. Kozikowski, 2014, Pharmacology research & perspectives.

Comprehensive Analysis of Two Shank 3 and the Cacna 1 c Mouse Models of Autism Spectrum Disorder Short title : Shank 3 and Cacna 1 c Models of ASD

Anirvan Ghosh, D. Brunner, W. Spooren, 2016 .